WebApr 8, 2024 · Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets … WebJan 11, 2024 · Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I/II Study of BT8009 at the 2024 ASCO Genitourinary (GU) Cancers Symposium ... On Tuesday, February 14, 2024 at 8:00 a.m. ET, the Company will host a conference call with BT8009 investigator Dr. Capucine Baldini (Medical Oncologist, Gustave Roussy) …
Bicycle Therapeutics to Present End of Dose Escalation Data from ...
WebBT8009 exhibited a favorable preclinical profile and was effective in a range of cell-derived xenograph tumor models. Methods: Study BT8009-100 (NCT04561362) will evaluate safety and tolerability of weekly and every other week BT8009 administration, alone and in combination with q4w nivolumab. WebApr 11, 2024 · Conference Call Details Bicycle Therapeutics will host a conference call and webcast today at 8:30 a.m. ET to review the data being presented. To access the call, please dial (800) 377-9118 (domestic) or (409) 937-8920 (international) and provide the Conference ID 2775710. reservationless conference call providers
Discovery of BT8009: A Nectin-4 Targeting Bicycle Toxin
WebFeb 15, 2024 · Since Bicycle’s BT8009 is one of only four nectin-4-targeting industry projects apart from Seagen’s Padcev, its maker is positioning it as a key pipeline asset. … Web• BT8009 is designed to have rapid tumor penetration and a short terminal plasma half-life, associated with rapid release and prolonged retention of ... ASCO 2024 Abstract Number: TPS2668. For additional information, please contact Dr. McKean at [email protected]. BT8009 in Xenograft Tumor Models. 0 7 14 21 0 100 200 300 400 500 600 700 800 900 WebIn this, BT8009 shows potent efficacy in multiple tumor models, including patient-derived xenografts, across a variety of tumor indications and is well-tolerated in preclinical safety studies. In several models it demonstrated … reservationless conference calling